Diabetes Metab J 44(6):80218 Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS et al (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
This places Retatrutide among the most potent pharmacological weight management agents studied to date
Meanwhile, influencers pitching wellness optimization strategies, and Make America Healthy Again proponents who promote thinness as virtuousness, have revived diet culture after it fell out of favor in the late 2010s
Here are some general things people may experience, though individual results vary: Results (if any) may take longer to appear compared to standard dosing, as reaching a therapeutic dose is a much more gradual process
Keep a record of: Energy levels Appetite changes Weight fluctuations This documentation helps you and your provider make timely decisions about transitioning to a maintenance phase or tapering off